Abstract
Background Pulmonary Rehabilitation (PR) is one of the most cost-effective therapies for chronic obstructive pulmonary disease (COPD) management. There are, however, people who do not respond to PR and reasons for non-response are mostly unknown. PR is likely to change the airway microbiota and this could play a role in its responsiveness. In this study we have explored the association between PR effectiveness and specific alterations in oral microbiota and inflammation.
Methods A prospective longitudinal study was conducted. Data on exercise capacity, dyspnoea, impact of disease and 418 saliva samples were collected from 76 patients, half of whom participated in a 12-weeks PR programme. Responders and non-responders to PR (dyspnoea, exercise-capacity and impact of disease) were defined based on minimal clinically important differences.
Results Changes in microbiota, including Prevotella melaninogenica and Streptococcus were observed upon PR. Prevotella, previously found to be depleted in severe COPD, increased during the first month of PR in responders. This increase was negatively correlated with Streptococcus and Lautropia, known to be enriched in severe cases of COPD. Simultaneously, an anti-inflammatory commensal of the respiratory tract, Rothia, correlated strongly and negatively with several pro-inflammatory markers, whose levels were generally boosted by PR.
Conversely, in non-responders, the observed decline in Prevotella correlated negatively with Streptococcus and Lautropia whose fluctuations co-occurred with several pro-inflammatory markers.
Conclusions PR is associated with changes in oral microbiota. Specifically, PR increases salivary Prevotella melaninogenica and avoids the decline in Rothia and the increase in Streptococcus and Lautropia in responders, which may contribute to the benefits of PR.
Notation of prior abstract publication/presentation S. Melo-Dias, M. Cabral, A. Furtado, S. Souto-Miranda, J. Cravo, M. A. Mendes, C. R. Almeida, A. Marques, A. Sousa, 2022, “Responsiveness to pulmonary rehabilitation is related with changes in oral microbiota of people with COPD” (Oral communication in 38° Congresso de Pneumologia, November 2022)
S. Melo-Dias, M. Cabral, A. Furtado, S. Souto-Miranda, J. Cravo, M. A. Mendes, C. R. Almeida, A. Marques, A. Sousa, 2022, “Pulmonary rehabilitation changes the oral microbiota of people with COPD” (Oral communication in ERS International Congress, September 2022)
S. Melo-Dias, M. Cabral, A. Furtado, S. Souto-Miranda, C. R. Almeida, A. Marques, A. Sousa, 2022, “The Effectiveness of pulmonary rehabilitation in COPD is associated with specific shifts in oral microbiota” (Poster presentation in the 7th meeting of International Society for Evolution, Medicine and Public Health, July 2022)
A. Furtado, S. Melo-Dias, M. Cabral, A. Marques, A. Sousa, 2021, “The effect of pulmonary rehabilitation in salivary microbiota of people with chronic obstructive pulmonary disease: A longitudinal study” (Poster presentation in IV International Conference - “Microbiota and Health”, 22 October 2021)
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://pubmed.ncbi.nlm.nih.gov/31151409/
Funding Statement
This study is integrated in PRIME, Pulmonary Rehabilitation and microbiota in exacerbations of COPD GENIAL, Genetic and Clinical markers of COPD trajectory and MicroAgeing, The role of microbiota in ageing, funded by Programa Operacional de Competitividade e Internacionalizacao, COMPETE, through Fundo Europeu de Desenvolvimento Regional - FEDER (POCI-010145-FEDER-028806 and POCI-01-0145-FEDER-007628), Fundacao para a Ciencia e Tecnologia - FCT (PTDC/DTP-PIC/2284/2014, PTDC/SAU-SER/28806/2017 and PTDC/BIA-EVL/30212/2017) and under the project UIDB/04501/2020. S. Melo-Dias was supported by Grant SFRH/BD/140908/2018 from FCT. A. Sousa was funded from national funds through FCT, Fundacao para a Ciencia e a Tecnologia, I.P., under the Scientific Employment Stimulus - Institutional Call - reference CEECINST/00026/2018.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
A cross-sectional study was conducted. Ethical approvals were obtained from Administracao Regional de Saude Centro (64/2016) and from Centro Hospitalar do Baixo Vouga (08-03-17). Written informed consent was obtained from all participants.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: This study is integrated in “PRIME – Pulmonary Rehabilitation and microbiota in exacerbations of COPD”, “GENIAL – Genetic and Clinical markers of COPD trajectory”, and “MicroAgeing - The role of microbiota in ageing”, funded by Programa Operacional de Competitividade e Internacionalização - COMPETE, through Fundo Europeu de Desenvolvimento Regional - FEDER (POCI-01-0145-FEDER-007628 and POCI-010145-FEDER-028806), Fundação para a Ciência e Tecnologia - FCT (PTDC/SAU-SER/28806/2017, PTDC/DTP-PIC/2284/2014 and PTDC/BIA-EVL/30212/2017) and under the project UIDB/04501/2020. S. Melo-Dias was supported by Grant SFRH/BD/140908/2018 from FCT. S. Souto-Miranda was supported by Grant SFRH/BD/146134/2019. A. Sousa was funded from national funds through FCT – Fundação para a Ciência e a Tecnologia, I.P., under the Scientific Employment Stimulus - Institutional Call - reference CEECINST/00026/2018.
Abstract: Conclusions were rewritten Methods: a full description of how saliva samples were collected and handled was added
Data Availability
The dataset supporting the conclusions of this article is included within the article (and its additional file(s)). Furthermore, raw sequencing data was deposited in National Centre for Biotechnology Informations (NCBI) Sequence Read Archive (SRA) (BioProject PRJNA872131).
